MatBA® for Diffuse Large B-cell Lymphoma (DLBCL)
Diffuse Large B-cell Lymphoma (DLBCL) is the most common form of Non-Hodgkin Lymphoma (NHL), accounting for up to one third of newly diagnosed cases. The median age of DLBCL patients is 64 years old. The disease is usually seen in adults, but may also be seen in young people. Each year in the US, approximately 20,000 new cases of DLBCL are diagnosed and approximately 10,000 people die from the disease. Despite being an aggressive disease, DLBCL is potentially curable. The first sign of DLBCL is usually rapid swelling in the neck, armpit, or groin caused by enlarged lymph nodes.
MatBA®-DLBCL is an array-CGH based assay that provides relevant prognostic values. When used in conjunction with other available prognostic indicators such as the international prognostic index (IPI), MatBA®-DLBCL can help predict a more accurate prognostication, and aid clinicians in therapy selection.
The MatBA®-DLBCL Array-CGH Assay is CLIA approved and New York State licensed. Fifteen distinct chromosomal regions are reported. These regions provide valuable prognostic data and critical information about the risk of progression of the disease. They are divided into two groups: group 1 which encompasses regions found in silico study, and group 2 including regions described in the literature.
MatBA®-DLBCL identifies information on 15 distinct chromosomal regions, providing valuable diagnostic data and critical information about the risk of progression of the disease.
|Reported Loci||Genomic Aberration|
|CDKN2A-TP53-RB-E2F Axis Aberrations||Genomic Aberration|
The MatBA®-DLBCL Array-CGH assay is part of CGI DLBCL CompleteSM program. This unique program is intended to provide clinicians with a one-stop-shop solution for the clinical management of DLBCL patients. The DLBCL CompleteSM program includes proprietary tests and the most relevant tests available for the clinical management of this aggressive lymphoma.